Optimization of meropenem dosage in the critically ill population based on renal function
Tóm tắt
Từ khóa
Tài liệu tham khảo
Merrem (2007) (Meropenem) package insert. AstraZeneca, Wilmington
Li C, Kuti JL, Nightingale CH, Nicolau DP (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46:1171–1178
Clinical Laboratory Standard Institute (2008) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI Publication M07-A8, Wayne
DeRyke CA, Kuti JL, Nicolau DP (2007) Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 58:337–344
Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T (2008) Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid. J Infect Chemother 14:330–332
Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2:289–300
Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851 quiz 859
Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA (2001) Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 45:13–22
Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL (2009) Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 25:69–77
Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142–150
Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F (1996) High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl 686:19–26
Leary RJ, Schumitzky A, Van Guilder M (2001) An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings, fouteenth IEEE symposium on computer-based medical systems. IEEE Computer Society, Bethesda, pp 389–394
Crandon JL, Kuti JL, Jones RN, Nicolau DP (2009) Comparison of 2002–2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother 43:220–227
Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA (2002) Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 19:105–110
Krueger WA, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, Drusano GL, Sorgel F (2005) Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 49:1881–1889
Lee DG, Choi SM, Shin WS, Lah HO, Yim DS (2006) Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 28:333–339
Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR (2005) Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 44:539–549
Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43:523–527
Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C (1999) Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 55:1878–1884
Lipman J, Wallis SC, Boots RJ (2003) Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 97:1149–1154 (table of contents)
Chow KM, Hui AC, Szeto CC (2005) Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 24:649–653
Bulik CC, Quintiliani Jr R, Samuel Pope J, Kuti JL, Nicolau DP (2009) Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis—a review of 3 cases. Resp Med CME E pub